I am sharing my journey to give a voice to patients who suffer from extreme poly-pathology and are often left behind by the medical system. I know that my medical…
For decades, colorectal cancer treatment has followed the same playbook: surgeons remove the tumor, then patients endure months of chemotherapy hoping to catch any remaining cancer cells. Yet even with…
AskBio Inc., a gene therapy company operating independently under Bayer AG, has taken a key step forward in the development of its investigational Parkinson’s disease therapy by transitioning to a…
Editor's Note: This story was originally published on Linked-In and is shared with permission by Olga Lucia Torres. In college, a clinician told me I was overdoing it. Then moved…
Enpatoran offers hope for millions suffering from lupus skin manifestations Pharmaceutical company Merck KGaA has announced a significant milestone in lupus treatment research. As reported by Business Wire, the first…
As reported on PharmaBiz, Vanda Pharmaceuticals has launched a new clinical trial, known as Thetis, to evaluate whether its neurokinin‑1 (NK‑1) receptor antagonist Nereus (tradipitant) can prevent vomiting associated with…
Editor's Note: Patient Worthy is honored to present this article, shared with us by our friends at the Seena Magowitz Foundation. When doctors diagnosed Michael Fitzpatrick with pancreatic neuroendocrine tumors…
A major breakthrough for the 300 Irish patients living with butterfly skin. For the first time in Ireland, patients battling epidermolysis bullosa, a rare and devastating skin condition, now have…
Editor's Note: Patient Worthy is honored to share this story submitted to us by Regina Portnoy, a clinical researcher with over 20 years of experience. Every year, as Mother’s Day…
Editor's Note: Patient Worthy is honored to share this patient story from our friends at Elephants & Tea. To see the story in its original format, please click here. This…
As shared on drugs.com, Vascarta Inc. has reported encouraging results from a Phase 1b clinical study evaluating its investigational topical/transdermal curcumin gel, VAS-101, for the treatment of knee pain associated…
Editor's Note: Patient Worthy is honored to share this article from our friends at the Brighter Hope Foundation. To see the article in its original format, please click here. Sir’Savion…
Labcorp announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic designed to identify patients with platinum-resistant ovarian cancer who may be eligible for…
As reported on drugs.com, Revolution Medicines has reported practice-changing efficacy results from a pivotal Phase 3 trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), one of the…
This, year the PCBers will meet in Indianapolis, Indiana. They will be celebrating 30 years as a community, as well as celebrating a much brighter future with the rare, autoimmune…
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to IMAAVY® (nipocalimab-aahu), marking a significant milestone as the first therapy to receive this…
As reported on Business Wire, Enveda, a clinical-stage biotechnology company focused on discovering novel small-molecule medicines, has reported encouraging results from a Phase 1b study evaluating its investigational therapy ENV-294…
A recent article from Inside Precision Medicine states: For decades, systemic lupus erythematosus (SLE) has resisted tidy solutions, a shapeshifting autoimmune disease that crosses into different organ systems, flares without…
AstraZeneca has announced positive results from the pivotal phase III MIRANDA trial of tozorakimab, a groundbreaking first-in-class monoclonal antibody designed to treat Chronic Obstructive Pulmonary Disease (COPD). According to PharmaBiz.com,…
On January 20, 2014, at 54 years old, I experienced what I casually called an “anxiety numbness event.” My left thumb and index finger went numb, followed by my left…
The US Food and Drug Administration (FDA) has approved Idvynso, a groundbreaking two-drug single-tablet regimen combining 100 mg doravirine and 0.25 mg islatravir, for treating HIV-1 infection in adults. As…
My story began very suddenly on May 4th, 2025, when I was home from graduate school visiting my family. It had been a great day, shopping and enjoying dinner at…
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults and remains one of the most difficult cancers to treat. Characterized by aggressive growth and diffuse microscopic spread,…
WebMD published a story about a young woman, Maddie, who had spent nine years in wheelchair confinement resulting from a rare metabolic disease related to kidney stones. As her doctor…
Health Canada has officially approved Cysklar® (cysteamine ophthalmic solution) 0.44%, marking a significant breakthrough for Canadians living with cystinosis. According to BusinessWire.com, the approval enables patients to access a topical…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
